Haffar S, Bazerbachi F, Leise M D, Dillon J J, Albright R C, Murad M H, Kamath P S, Watt K D
Digestive Center for Diagnosis & Treatment, Damascus, Syrian Arab Republic.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Aliment Pharmacol Ther. 2017 Nov;46(9):790-799. doi: 10.1111/apt.14285. Epub 2017 Sep 4.
Hepatitis E virus (HEV) infection appears to be more common than previously thought. HEV seroprevalence in patients on maintenance haemodialysis (HD) is unclear with a range from 0% to 44%. In addition, risk factors of transmission of HEV in patients on haemodialysis are unknown.
To perform a systematic review and meta-analysis of HEV seroprevalence in HD patients compared with controls.
A systematic search of several databases identified all observational studies with comparative arms. Two reviewers extracted data and assessed the methodological quality. A random-effects model was used for pooled odds ratio (OR) and 95% confidence interval (CI) of positive anti-HEV IgG in both groups. Heterogeneity and publication bias were assessed with appropriate tests.
We identified 31 studies from 17 countries between 1994 and 2016. Sixteen studies were judged to have adequate quality and 15 to have moderate limitations. HEV infection was more prevalent in patients on haemodialysis compared with controls (OR 2.47, 95% CI 1.79-3.40, I = 75.2%, P < .01). We conducted several subgroup analyses without difference in results. Egger regression test did not suggest publication bias (P = .83). Specific risk factors of HEV transmission in patients on haemodialysis were not clearly identified.
Hepatitis E virus infection is more prevalent in patients on haemodialysis compared with non-haemodialysis control groups. Further studies are needed to determine risk factors of acquisition, impact on health, and risk for chronic HEV especially among those patients going to receive organ transplantation.
戊型肝炎病毒(HEV)感染似乎比之前认为的更为常见。维持性血液透析(HD)患者中HEV的血清流行率尚不清楚,范围在0%至44%之间。此外,血液透析患者中HEV传播的危险因素尚不清楚。
对HD患者与对照组相比的HEV血清流行率进行系统评价和荟萃分析。
对多个数据库进行系统检索,确定所有具有比较组的观察性研究。两名评价者提取数据并评估方法学质量。采用随机效应模型计算两组抗HEV IgG阳性的合并比值比(OR)和95%置信区间(CI)。用适当的检验评估异质性和发表偏倚。
我们在1994年至2016年间确定了来自17个国家的31项研究。16项研究被判定质量 adequate,15项有中度局限性。与对照组相比,血液透析患者中HEV感染更为普遍(OR 2.47,95%CI 1.79 - 3.40,I = 75.2%,P <.01)。我们进行了多项亚组分析,结果无差异。Egger回归检验未提示发表偏倚(P =.83)。血液透析患者中HEV传播的具体危险因素未明确确定。
与非血液透析对照组相比,血液透析患者中戊型肝炎病毒感染更为普遍。需要进一步研究以确定感染的危险因素、对健康的影响以及慢性HEV的风险,尤其是在那些即将接受器官移植的患者中。